Toxicology is a borrowing science, using what is known about the physicochemical properties of a test article (e.g., potential therapeutic) and biology of the intended target (e.g., receptor) hypothesized to modulate the disease of interest. Prior to entering first in human clinical trials, rigorous in silico, in vitro and in vivo testing must produce tolerability data supporting safe use of the test article for its intended use (i.e., drug label). Topics covering early and required toxicology testing will be covered.

Presented by: Kenneth J. Olivier Jr., PhD, Head of Toxicology and various drug development activities at Orange Grove Bio, VP of Development at TScan Therapeutics, Inc., Director of nonclinical development at Boston Immune Technologies and Therapeutics, President Olivier KOnsulting